Ruxolitinib + Navitoclax

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelofibrosis (MF)

Conditions

Myelofibrosis (MF)

Trial Timeline

Oct 31, 2017 → Jan 29, 2025

NCT ID

NCT03222609

About Ruxolitinib + Navitoclax

Ruxolitinib + Navitoclax is a phase 2 stage product being developed by AbbVie for Myelofibrosis (MF). The current trial status is completed. This product is registered under clinical trial identifier NCT03222609. Target conditions include Myelofibrosis (MF).

What happened to similar drugs?

2 of 19 similar drugs in Myelofibrosis (MF) were approved

Approved (2) Terminated (3) Active (14)

✅ruxolitinib + panobinostatNovartisApproved

✅INC424NovartisApproved

🔄Placebo for Navitoclax + Ruxolitinib + NavitoclaxAbbViePhase 3

🔄Navitoclax + Ruxolitinib + Best Available Therapy (BAT)AbbViePhase 3

❌Ruxolitinib + Ruxolitinib PlaceboNovartisPhase 3

🔄INC424NovartisPhase 3

🔄Pelabresib + Ruxolitinib + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03222609	Phase 2	Completed	Oct 31, 2017	Jan 29, 2025	Myelofibrosis (MF)

Competing Products

20 competing products in Myelofibrosis (MF)

See all competitors

Product	Company	Stage	Hype Score
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Nusivertib + Ruxolitinib + Momelotinib	Sumitomo Pharma	Phase 1/2	39
ABBV-744 + Navitoclax + Ruxolitinib	AbbVie	Phase 1	33
Placebo for Navitoclax + Ruxolitinib + Navitoclax	AbbVie	Phase 3	40
Mivebresib + Navitoclax + Ruxolitinib	AbbVie	Phase 1	21
Navitoclax + Venetoclax	AbbVie	Pre-clinical	26
Navitoclax + Ruxolitinib + Best Available Therapy (BAT)	AbbVie	Phase 3	44
NS-018 + Best Available Therapy	Nippon Shinyaku	Phase 2	27
AZD1480	AstraZeneca	Phase 1	29
Bomedemstat	Merck	Phase 2	31
Peginterferon alfa-2a	Merck	Phase 2	27
Bomedemstat	Merck	Phase 1/2	32
MBG453 + NIS793 + Spartalizumab + Decitabine	Novartis	Phase 1	21
PIM447 + Ruxolitinib + LEE011	Novartis	Phase 1	29
LDE225 + INC424	Novartis	Phase 1/2	32
Imatinib mesylate	Novartis	Phase 2	35
Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793	Novartis	Phase 1/2	24
Ruxolitinib + Ruxolitinib Placebo	Novartis	Phase 3	32
Ruxolitinib	Novartis	Pre-clinical	30
ruxolitinib	Novartis	Phase 2	35